Literature DB >> 15534885

Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials.

Kevin P Weinfurt1, Venita Depuy, Liana D Castel, Daniel P Sulmasy, Kevin A Schulman, Neal J Meropol.   

Abstract

BACKGROUND: There is concern that patients with poor numeracy may have difficulty understanding the information necessary to make informed treatment decisions. The authors sought to characterize a special form of numeracy among patients with advanced cancer who were offered participation in Phase I oncology clinical trials.
METHODS: Surveys were administered to 328 cancer patients who were considering Phase I trials. Their frequency-type numeracy was assessed using a multiple-choice question involving a hypothetical scenario in which a physician stated that an experimental treatment would control cancer in "40% of cases like yours." In univariate and multivariable analyses, patient characteristics that were associated with better numeracy were identified.
RESULTS: The correct frequency-type interpretation was selected by 72% of respondents. Fourteen percent of respondents incorrectly selected a belief-type answer, "The doctor is 40% confident that the treatment will control my cancer." In a multivariable model, patients who answered incorrectly tended to have less formal education and less experience with experimental therapies.
CONCLUSIONS: Because the misunderstandings some patients demonstrated may influence their treatment decision making adversely, it is critical to identify such patients and to give them special consideration when communicating information about potential risks and benefits of treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15534885     DOI: 10.1002/cncr.20730

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Communication and informed consent in phase 1 trials: a review of the literature.

Authors:  A C Cox; L J Fallowfield; V A Jenkins
Journal:  Support Care Cancer       Date:  2006-01-28       Impact factor: 3.603

2.  Prognostic factors among cancer patients with good performance status screened for phase I trials.

Authors:  Nicolas Penel; Marie Vanseymortier; Marie-Edith Bonneterre; Stéphanie Clisant; Eric Dansin; Yvette Vendel; Régis Beuscart; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2007-09-22       Impact factor: 3.850

3.  Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials.

Authors:  Michelle Lally; Richard Goldsworthy; Moussa Sarr; Jessica Kahn; Larry Brown; Ligia Peralta; Gregory Zimet
Journal:  J Adolesc Health       Date:  2014-03-05       Impact factor: 5.012

Review 4.  Recommendations for enhancing clinical trials education: a review of the literature.

Authors:  Karen A Stepan; Amy P Gonzalez; Vivian S Dorsey; Debra K Frye; Nita D Pyle; Regina F Smith; Terry A Throckmorton; Louise A Villejo; Scott B Cantor
Journal:  J Cancer Educ       Date:  2011-03       Impact factor: 2.037

Review 5.  Communication and informed consent in phase 1 trials: a review of the literature from January 2005 to July 2009.

Authors:  Valerie A Jenkins; John L Anderson; Lesley J Fallowfield
Journal:  Support Care Cancer       Date:  2010-03-04       Impact factor: 3.603

6.  Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?

Authors:  Kevin P Weinfurt; Damon M Seils; Li Lin; Daniel P Sulmasy; Alan B Astrow; Herbert I Hurwitz; Roger B Cohen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

Review 7.  How numeracy influences risk comprehension and medical decision making.

Authors:  Valerie F Reyna; Wendy L Nelson; Paul K Han; Nathan F Dieckmann
Journal:  Psychol Bull       Date:  2009-11       Impact factor: 17.737

8.  An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study.

Authors:  Joanne S Buzaglo; Jennifer L Millard; Caroline G Ridgway; Eric A Ross; Susan P Antaramian; Suzanne M Miller; Neal J Meropol
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

9.  Decisional conflict among patients who accept or decline participation in phase I oncology studies.

Authors:  Kathryn E Flynn; Kevin P Weinfurt; Damon M Seils; Li Lin; Caroline B Burnett; Kevin A Schulman; Neal J Meropol
Journal:  J Empir Res Hum Res Ethics       Date:  2008-09       Impact factor: 1.742

10.  Health literacy-listening skill and patient questions following cancer prevention and screening discussions.

Authors:  Kathleen M Mazor; Donald L Rubin; Douglas W Roblin; Andrew E Williams; Paul K J Han; Bridget Gaglio; Sarah L Cutrona; Mary E Costanza; Joann L Wagner
Journal:  Health Expect       Date:  2015-07-22       Impact factor: 3.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.